HMGB1 and melanoma: Moreover, the GSDME protein levels in cancer cells are not as invariable as those in normal cells [73], and BRAF/MEK inhibitors can promote the cleavage of GSDME and the release of high-mobility group box 1 (HMGB1), which are markers of pyroptotic cell death in melanoma cells [74].